Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS.
CompletedPhase 2, Phase 3NCT02063126
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The main objective is evaluate to safety and efficacy of oral Reconnect ® (food supplementation composed by Coenzyme Q10, NADH, phosphoserine y vitamin C) on the maximum HR during an exercise test in CFS
Study details
- Official title
- A Randomized, Double-blind, Placebo-controlled, Comparative Clinical Trial to Measure the Maximun Heart Rate During a Cycle Ergometer Test After ReConnect® Supplementation in CFS.
- Conditions
- Interventions
- Dietary supplement: ReConnect (NADH plus CoQ10)
- Dietary supplement: placebo
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
- Collaborators
- VITAE NATURAL NUTRITION, S.L.
- Start date
- 2013-01
- Primary completion
- 2013-01
- Sex
- Female
- Age range
- from 18 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- Spain
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients female between 18 and 65 years old. * CFS patients diagnosed with Chronic Fatigue Syndrome (CFS Clinical Unit, Vall d'Hebron Hospital, Barcelona, Spain) * Heart rate in radial pulse and seated between 50 to100 bpm, systolic BP between 100 to 140 mm Hg and diastolic BP between 50 to 90 mm Hg. * Patients who give a written informed consent before initiating the study. Exclusion Criteria: * Patients for that is contraindicated or is not advisable to carry-out an ergometer exercise test. * Patients who are participating in another clinical trial of the same or differents nature in the last 30 days prior to inclusion. * Any participants who, in the opinion of the investigator, may not be able to follow instructions or make a good treatment compliance. * Subjects that do not give written informed consent to participate in the study. * Participants who are receiving any drug or banned substances and is expected that withdrawal of some medications/products not allowed in the study involves a significants problem.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02063126